Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Revisiting variation in the somatic mutation landscape of non-small cell lung cancer.
Pathak V et al.
Hgg Advances, 2025
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study.
Randon G et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects.
Ishiyama N et al.
Cancer Research, 2023
Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing.
Ahn BC et al.
Cancer Research and Treatment, 2023
The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review.
Vaghi C et al.
Cancer Treatment Reviews, 2023
Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene.
Torres-Jiménez J et al.
Cancers, 2022
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer.
Lazzari L et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2019
HER2+ mCRC patients with exon 20 R784G substitution mutation do not respond to the cetuximab therapy.
Gharib E et al.
Journal of Cellular Physiology, 2019
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case.
Martinelli E et al.
Esmo Open, 2018
Genomic alterations of ERBB receptors in cancer: clinical implications.
Mishra R et al.
Oncotarget, 2017
Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer.
Shimada Y et al.
Human Pathology, 2017
Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.
Parikh A et al.
Journal of the National Comprehensive Cancer Network : Jnccn, 2017
Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer.
Aung KL et al.
Cold Spring Harbor Molecular Case Studies, 2016
The genomic landscape of response to EGFR blockade in colorectal cancer.
Bertotti A et al.
Nature, 2015
HER2 activating mutations are targets for colorectal cancer treatment.
Kavuri SM et al.
Cancer Discovery, 2015